Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Butrus Atrash

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|November 8, 2013
Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cellsVassilios Bavetsias, Amir Faisal, Simon Crumpler, et al.
Journal of Medicinal Chemistry|October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaVassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.
Journal of Medicinal Chemistry|June 23, 2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidateVassilios Bavetsias, Jonathan M Large, Chongbo Sun, et al.
Epigenetics & Chromatin|March 8, 2017
Assessing histone demethylase inhibitors in cells: lessons learnedStephanie B Hatch, Clarence Yapp, Raquel C Montenegro, et al.
Journal of Medicinal Chemistry|November 22, 2013
Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)Sébastien Naud, Isaac M Westwood, Amir Faisal, et al.
European Journal of Medicinal Chemistry|June 4, 2019
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assaysYann-Vaï Le Bihan, Rachel M Lanigan, Butrus Atrash, et al.
Journal of Medicinal Chemistry|January 8, 2016
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase InhibitorsVassilios Bavetsias, Rachel M Lanigan, Gian Filippo Ruda, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|November 8, 2013
Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cellsVassilios Bavetsias, Amir Faisal, Simon Crumpler, et al.
Journal of Medicinal Chemistry|October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaVassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.
Journal of Medicinal Chemistry|June 23, 2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidateVassilios Bavetsias, Jonathan M Large, Chongbo Sun, et al.
Epigenetics & Chromatin|March 8, 2017
Assessing histone demethylase inhibitors in cells: lessons learnedStephanie B Hatch, Clarence Yapp, Raquel C Montenegro, et al.
Journal of Medicinal Chemistry|November 22, 2013
Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)Sébastien Naud, Isaac M Westwood, Amir Faisal, et al.
European Journal of Medicinal Chemistry|June 4, 2019
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assaysYann-Vaï Le Bihan, Rachel M Lanigan, Butrus Atrash, et al.
Journal of Medicinal Chemistry|January 8, 2016
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase InhibitorsVassilios Bavetsias, Rachel M Lanigan, Gian Filippo Ruda, et al.
Pageof 2